Skip to main content
Hit enter to search or ESC to close
Search
Close Search
Menu
About
Leadership
Board of Directors
Portfolio
Hepatocellular Carcinoma
Gravitas Life Sciences
Newsroom
Investors
Investor Overview
Press Releases
Presentations
Stock Information
SEC Filings
Corporate Governance
Contact
Menu
Investor Overview
Press Releases
Presentations
Stock Information
SEC Filings
Corporate Governance
Press Releases
All Press Releases
Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
October 19, 2026
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
October 14, 2026
Close Menu
About
Leadership
Board of Directors
Portfolio
Hepatocellular Carcinoma
Gravitas Life Sciences
Newsroom
Investors
Investor Overview
Press Releases
Presentations
Stock Information
SEC Filings
Corporate Governance
Contact
